Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. The reason vital signs are tracked throughout is unglamorous: ketamine raises blood pressure and heart rate transiently, and someone needs to be watching when it does. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment.
The trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. It is worth carrying that into every conversation with a the United States provider. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. The useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. For anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. It is the first thing to establish about any the United States programme. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system.
The background that makes the United States listings interpretable is this. A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
Cost, coverage and the numbers nobody posts
Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. For anyone weighing options in the United States, remote consultation paired with on-site administration is a sensible hybrid, and several programmes now structure themselves that way for travelling patients. Continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. Patients researching the United States providers run into this constantly. Someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood.
Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Because esketamine carries a Risk Evaluation and Mitigation Strategy, it can only be administered at certified centres with at least two hours of post-dose observation. Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. The United States listings on this page are organised so that this is checkable rather than assumed. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. Six infusions over roughly three weeks is the common induction pattern, though some programmes offer four and others extend to eight. Read against the United States market, an anaesthesiologist and a psychiatrist offering the same infusion are often running quite different programmes around it. A single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand.
What a properly run programme looks like from the inside
Anyone comparing the United States programmes will find this decisive: using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. That is as true in the United States as anywhere else in the country. That holds in the United States as it does everywhere: the phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Nothing about the United States changes that.
Set aside the United States for a moment, because the general position comes first. In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
In the United States the same rule applies: transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. Response, where it occurs, is frequently not permanent, and many people move onto maintenance sessions spaced every two to six weeks. Applied to the United States, the point is this: a consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all. Read against the United States market, travel time belongs in the treatment plan rather than being treated as a detail to solve later. Anyone comparing the United States programmes will find this decisive: the headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow.
What happens after the first course of treatment
A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. It is worth carrying that into every conversation with a the United States provider. In the United States the same rule applies: someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. For anyone weighing options in the United States, a clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. Telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. Headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. The United States listings on this page are organised so that this is checkable rather than assumed. Resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting. It is the first thing to establish about any the United States programme. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. Applied to the United States, the point is this: the relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring.
Risks, contraindications and honest caution
Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. Ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. Distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal. Nothing about the United States changes that. Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly. That is as true in the United States as anywhere else in the country.
The United States comparison only becomes useful once this is clear. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
That holds in the United States as it does everywhere: continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. Whether a programme titrates the dose according to response and tolerability, or runs a fixed protocol for everyone, is a meaningful difference in how individualised the care actually is. If the neuroplasticity hypothesis is right, what happens between sessions is not an optional extra but part of how the treatment is meant to function. Patients researching the United States providers run into this constantly. In the United States the same rule applies: whether a programme is led by someone trained in sedation or someone trained in mood disorders changes what gets emphasised and what gets assumed.
Common misunderstandings worth clearing up
Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. That is as true in the United States as anywhere else in the country. Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly. The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations.
Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
Read against the United States market, researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account. Applied to the United States, the point is this: the logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. That holds in the United States as it does everywhere: a standard induction runs to six sessions across two to three weeks, a figure inherited from early trial protocols rather than settled by comparative research. The reason vital signs are tracked throughout is unglamorous: ketamine raises blood pressure and heart rate transiently, and someone needs to be watching when it does. The clinicians running these programmes come from anaesthesiology, psychiatry, emergency medicine and pain management, and the route shapes how the treatment is framed. Patients researching the United States providers run into this constantly.
What to take from all of this
Anyone comparing the United States programmes will find this decisive: a driver is mandatory, and across six sessions in three weeks that means arranging somebody else's time repeatedly rather than once. Advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. It is the first thing to establish about any the United States programme. The induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.